English
Spanish
French
German
Italian
Dutch
Russian
Chinese (Simplified)
Japanese
Hindi
Hebrew
Portuguese
An aspect that is often overlooked during drug development is a cost-benefit analysis of a therapeutic treatment. Insurance companies often determine the level of coverage they are willing to provide… Read More »
Extraordinary Measures – Understanding the socioeconomic impact of FSHD
Artificial intelligence reveals some surprises
Analysis of FSHD registry data overturns prior ideas about genetic and gender factors by Natalie Katz, MD, University of Rochester Facioscapulohumeral muscular dystrophy is a highly variable disease. While we… Read More »
Extraordinary Measures – Many shots on goal
by Jamshid Arjomand, Chief Science Officer With a dozen or more potential FSHD therapies in the drug development pipeline, why is the FSHD Society continuing to invest substantial funds− a… Read More »
Extraordinary measures – An FSHD Society for everyone
by June Kinoshita, FSHD Society Our mission at the FSHD Society is to find treatments and a cure for FSHD—and then make sure everyone in the world who needs it… Read More »
His father’s FSHD inspired scientist to make a breakthrough
Is this the ticket to gene therapy for muscle diseases? by June Kinoshita, Director of Research and Patient Engagement A lot of emails cross my desk every day, but one… Read More »